Compugen (CGEN) Stock: Buy, Sell, or Hold?
CGEN - Compugen Ltd
$2.47
0.01 (0.41%)
â˛
5d:
-3.33%
30d:
-1.2%
90d:
+21.08%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 03, 2026
0d
Get Alerted When CGEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CGEN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CGEN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CGEN is currently trading at $2.47, which is considered fair relative to its 30-day fair value range of $2.37 to $2.67.
Technical Outlook: Technically, CGEN is in a downtrend. The price is currently testing key support at $2.43. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CGEN scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.60 (+86.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CGEN is in a downtrend. The price is currently testing key support at $2.43. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CGEN scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.60 (+86.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.37 -
$2.67
Company Quality Score
32/100
(SELL)
Options IV Signal
44th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
54.2%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Options fairly priced (IV 44th percentile)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 86.2% below Wall St target ($4.60)
- WARNING: Composite score 32/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.37 -
$2.67
Current vs Trading Range
FAIR
Expected Move (7 Days)
Âą$0.38
(15.4%)
Support & Resistance Levels
Support Level
$2.43
Resistance Level
$2.72
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.74
Wall Street Target
$4.60
(+86.2%)
Revenue Growth (YoY)
107.0%
Profit Margin
47.6%
Share & Embed Analysis
Last updated: September 13, 2026 10:25 PM ET
Data refreshes hourly during market hours. Next update: 11:25 PM
Data refreshes hourly during market hours. Next update: 11:25 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CGEN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Eran Ophir
SELL
5000 shares
2026-04-14
Zurit Levine
SELL
3125 shares
2026-04-10
Zurit Levine
SELL
5375 shares
2026-04-08
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 52 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$84 | 50 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |
|
GPCR
Structure Therapeutics IâĻ |
STRONG BUY
14 analysts |
$106 | 41 HOLD |
